603858 步长制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)8.354-5.0732.660-11.4768.297
总资产报酬率 ROA (%)4.465-2.7541.489-6.6794.972
投入资产回报率 ROIC (%)5.932-3.7382.021-8.8796.483

边际利润分析
销售毛利率 (%)62.30559.77068.15271.69173.781
营业利润率 (%)12.388-2.2423.292-8.35710.281
息税前利润/营业总收入 (%)13.058-2.2043.671-7.66410.958
净利润/营业总收入 (%)9.342-6.3821.147-10.6417.031

收益指标分析
经营活动净收益/利润总额(%)91.809-169.066258.509-135.174101.889
价值变动净收益/利润总额(%)1.866-3.5234.799-0.217-2.672
营业外收支净额/利润总额(%)-2.79532.450-10.5090.788-2.143

偿债能力分析
流动比率 (X)1.1451.0611.2081.2921.166
速动比率 (X)0.4930.4100.4890.7470.631
资产负债率 (%)48.53449.25645.54944.08239.967
带息债务/全部投入资本 (%)26.02225.37820.70520.11719.062
股东权益/带息债务 (%)270.738282.107365.294379.042411.068
股东权益/负债合计 (%)111.315107.311122.075127.755149.940
利息保障倍数 (X)12.974-1.9755.304-10.09312.278

营运能力分析
应收账款周转天数 (天)21.29040.24742.50037.21432.139
存货周转天数 (天)386.587388.435372.069324.192287.493